Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the National Database of Health Insurance Claims and Specific Health Checkups in Japan.
Adherence
Care gap
Medication possession ratio
Osteoporosis
Persistence
Pharmacotherapy
Journal
Archives of osteoporosis
ISSN: 1862-3514
Titre abrégé: Arch Osteoporos
Pays: England
ID NLM: 101318988
Informations de publication
Date de publication:
13 09 2021
13 09 2021
Historique:
received:
10
03
2021
accepted:
20
07
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
29
10
2021
Statut:
epublish
Résumé
In Japan, persistence and the 2-year MPR were inadequate in increasing fracture control efficacy despite a high adherence rate during the treatment period. Both factors were higher in females and those with polypharmacy but worsened with increasing age. Only a few large-scale studies have examined the care gap between the patients who need osteoporosis treatment and those who receive them in Japan. The aim of this study was to investigate the persistence and adherence to osteoporosis pharmacotherapy in Japan. Continuation (persistence) rates and adherence to osteoporosis pharmacotherapy were investigated using medical insurance data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan, between April 2012 and March 2019. The study included 528,806 male and 3,064,410 female patients. Persistence proportions were 56.6% in the first year and 46.3% in the second year. The medication possession ratio (MPR) from start to discontinuation of treatment (MPR In Japan, persistence and the 2-year MPR were inadequate in increasing fracture control efficacy despite a high adherence rate during the treatment period. To bridge the care gap following osteoporosis pharmacotherapy, improvements are required for males, the elderly, and those without polypharmacy.
Identifiants
pubmed: 34515872
doi: 10.1007/s11657-021-00993-8
pii: 10.1007/s11657-021-00993-8
doi:
Substances chimiques
Bone Density Conservation Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
131Informations de copyright
© 2021. International Osteoporosis Foundation and National Osteoporosis Foundation.
Références
Melton LJ 3rd, Achenbach SJ, Atkinson EJ, Therneau TM, Amin S (2013) Long-term mortality following fractures at different skeletal sites: a population-based cohort study. Osteoporos Int 24:1689–1696. https://doi.org/10.1007/s00198-012-2225-1
doi: 10.1007/s00198-012-2225-1
pubmed: 23212281
Svedbom A, Borgstöm F, Hernlund E, Ström O, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jürisson M, Kallikorm R, Lember M, Lesnyak O, McCloskey E, Sanders KM, Silverman S, Solodovnikov A, Tamulaitiene M, Thomas T, Toroptsova N, Uusküla A, Tosteson ANA, Jönsson B, Kanis JA (2018) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int 29:557–566. https://doi.org/10.1007/s00198-017-4317-4
doi: 10.1007/s00198-017-4317-4
pubmed: 29230511
pmcid: 29230511
Orimo H, Yaegashi Y, Hosoi T, Fukushima Y, Onoda T, Hashimoto T, Sakata K (2016) Hip fracture incidence in Japan: estimates of new patients in 2012 and 25-year trends. Osteoporos Int 27:1777–1784. https://doi.org/10.1007/s00198-015-3464-8
doi: 10.1007/s00198-015-3464-8
pubmed: 26733376
pmcid: 4873530
Cheung CL, Ang SB, Chadha M, Chow ES, Chung YS, Hew FL, Jaisamrarn U, Ng H, Takeuchi Y, Wu CH, Xia W, Yu J, Fujiwara S (2018) An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study. Osteoporos Sarcopenia 4:16–21. https://doi.org/10.1016/j.afos.2018.03.003
doi: 10.1016/j.afos.2018.03.003
pubmed: 30775536
pmcid: 6362950
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541. https://doi.org/10.1016/s0140-6736(96)07088-2
doi: 10.1016/s0140-6736(96)07088-2
pubmed: 8950879
pmcid: 8950879
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340. https://doi.org/10.1056/NEJM200102013440503
doi: 10.1056/NEJM200102013440503
pubmed: 11172164
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765. https://doi.org/10.1056/NEJMoa0809493
doi: 10.1056/NEJMoa0809493
Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44. https://doi.org/10.1007/s00198-018-4704-5
doi: 10.1007/s00198-018-4704-5
Chen YC, Lin WC (2017) Poor 1st-year adherence to anti-osteoporotic therapy increases the risk of mortality in patients with magnetic resonance imaging-proven acute osteoporotic vertebral fractures. Patient Prefer Adherence 11:839–843. https://doi.org/10.2147/PPA.S131564
doi: 10.2147/PPA.S131564
pubmed: 28490865
pmcid: 5414717
Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565–2573. https://doi.org/10.1007/s00198-011-1668-0
doi: 10.1007/s00198-011-1668-0
Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15:604–612. https://doi.org/10.1016/j.jval.2012.02.001
doi: 10.1016/j.jval.2012.02.001
pubmed: 22867768
Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14:571–581. https://doi.org/10.1016/j.jval.2010.11.010
doi: 10.1016/j.jval.2010.11.010
pubmed: 21669382
Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951. https://doi.org/10.1007/s00198-009-1134-4
doi: 10.1007/s00198-009-1134-4
pubmed: 19967338
Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9:e027049. https://doi.org/10.1136/bmjopen-2018-027049
doi: 10.1136/bmjopen-2018-027049
pubmed: 30987990
pmcid: 6500256
Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 29:2623–2637. https://doi.org/10.1007/s00198-018-4759-3
doi: 10.1007/s00198-018-4759-3
pubmed: 30417253
Fardellone P, Lello S, Cano A, de Sá ME, Watanabe de Oliveira R, Julian GS, Tang B (2019) Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review. Clin Ther 41:1576–1588. https://doi.org/10.1016/j.clinthera.2019.05.001
doi: 10.1016/j.clinthera.2019.05.001
pubmed: 31151814
van Boven JF, de Boer PT, Postma MJ, Vegter S (2013) Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab 31:562–570. https://doi.org/10.1007/s00774-013-0440-2
doi: 10.1007/s00774-013-0440-2
Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O (2017) Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. Medicare population. J Manag Care Spec Pharm 23:1178–1190. https://doi.org/10.18553/jmcp.2017.17054
doi: 10.18553/jmcp.2017.17054
pubmed: 29083977
Nakatoh S, Fujimori K, Tamaki J, Okimoto N, Ogawa S, Iki M (2021) Insufficient persistence of and adherence to osteoporosis pharmacotherapy in Japan. J Bone Miner Metab. https://doi.org/10.1007/s00774-020-01188-w
doi: 10.1007/s00774-020-01188-w
pubmed: 33403498
Sato M, Tsujimoto M, Kajimoto K, Uetake H, Shimoda H, Fujiwara S (2018) Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS). Arch Osteoporos 13:74. https://doi.org/10.1007/s11657-018-0487-8
doi: 10.1007/s11657-018-0487-8
pubmed: 29978364
pmcid: 6310708
Kishimoto H, Maehara M (2015) Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos 10:231. https://doi.org/10.1007/s11657-015-0231-6
doi: 10.1007/s11657-015-0231-6
pubmed: 26297076
Sakai A, Ikeda S, Okimoto N, Matsumoto H, Teshima K, Okazaki Y, Fukuda F, Arita S, Tsurukami H, Nagashima M, Yoshioka T (2014) Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study. Osteoporos Int 25:2245–2253. https://doi.org/10.1007/s00198-014-2756-8
doi: 10.1007/s00198-014-2756-8
pubmed: 24899103
pmcid: 4134483
Ministry of Health, Labour, and Welfare. The popularization and state of electronic receipt claims https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000099002.pdf . (in Japanese) Accessed March 09, 2021
Desai RJ, Mahesri M, Abdia Y, Barberio J, Tong A, Zhang D, Mavros P, Kim SC, Franklin JM (2018) Association of osteoporosis medication use after hip fracture with prevention of subsequent nonvertebral fractures: an instrumental variable analysis. JAMA Netw Open 1:e180826. https://doi.org/10.1001/jamanetworkopen.2018.0826
doi: 10.1001/jamanetworkopen.2018.0826
pubmed: 30646034
pmcid: 6324295
Cheung MY, Ho AW, Wong SH (2018) Post-fracture care gap: a retrospective population-based analysis of Hong Kong from 2009 to 2012. Hong Kong Med J 24:579–583. https://doi.org/10.12809/hkmj187227
doi: 10.12809/hkmj187227
pubmed: 30449735
Nakatoh S, Fujimori K, Tamaki J, Okimoto N, Ogawa S, Iki M (2020) Insufficient increase in bone mineral density testing rates and pharmacotherapy after hip fracture in Japan Journal of Bone and Mineral Metabolism. J Bone Miner Metab 38:589–596. https://doi.org/10.1007/s00774-020-01093-2
doi: 10.1007/s00774-020-01093-2
pubmed: 32146508
Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12:22. https://doi.org/10.1007/s11657-017-0316-5
doi: 10.1007/s11657-017-0316-5
pubmed: 28243883
pmcid: 5329075
Reyes C, Tebe C, Martinez-Laguna D, Ali MS, Soria-Castro A, Carbonell C, Prieto-Alhambra D (2017) One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int 28:2997–3004. https://doi.org/10.1007/s00198-017-4144-7
doi: 10.1007/s00198-017-4144-7
pubmed: 28714038
Neele SJ, Evertz R, De Valk-De RG, Roos JC, Netelenbos JC (2002) Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30:599–603. https://doi.org/10.1016/s8756-3282(01)00706-2
doi: 10.1016/s8756-3282(01)00706-2
pubmed: 11934652
Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507–1513. https://doi.org/10.1359/JBMR.050501
doi: 10.1359/JBMR.050501
pubmed: 16059622
Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365–372. https://doi.org/10.1007/s00198-007-0460-7
doi: 10.1007/s00198-007-0460-7
pubmed: 17938986
Nakatoh S (2017) Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change. Osteoporos Sarcopenia 3:45–52. https://doi.org/10.1016/j.afos.2016.12.001
doi: 10.1016/j.afos.2016.12.001
pubmed: 30775502
pmcid: 6372821
Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291–1296. https://doi.org/10.1002/jbmr.3110
doi: 10.1002/jbmr.3110
pubmed: 28240371
McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723–1732. https://doi.org/10.1007/s00198-017-3919-1
doi: 10.1007/s00198-017-3919-1
pubmed: 28144701
pmcid: 5391373
Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki EM, Harris ST (2017) Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years. Osteoporos Int 28:1355–1363. https://doi.org/10.1007/s00198-016-3886-y
doi: 10.1007/s00198-016-3886-y
pubmed: 28058444
Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022. https://doi.org/10.4065/81.8.1013
doi: 10.4065/81.8.1013
pubmed: 16901023
Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24:37–55. https://doi.org/10.2165/00002512-200724010-00003
doi: 10.2165/00002512-200724010-00003
pubmed: 17233546
Dyer SM, Crotty M, Fairhall N, Magaziner J, Beaupre LA, Cameron ID, Sherrington C, Fragility Fracture Network (FFN) Rehabilitation Research Special Interest Group (2016) A critical review of the long-term disability outcomes following hip fracture. BMC Geriatr 16:158. https://doi.org/10.1186/s12877-016-0332-0
doi: 10.1186/s12877-016-0332-0
pubmed: 5010762
pmcid: 5010762
Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20:299–307. https://doi.org/10.1007/s00198-008-0651-x
doi: 10.1007/s00198-008-0651-x
pubmed: 18551241
Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005. https://doi.org/10.1093/oxfordjournals.aje.a116756
doi: 10.1093/oxfordjournals.aje.a116756
pubmed: 8317445
Lee SB, Park Y, Kim DW, Kwon JW, Ha JW, Yang JH, Lee BH, Suk KS, Moon SH, Kim HS, Lee HM (2020) Association between mortality risk and the number, location, and sequence of subsequent fractures in the elderly. Osteoporos Int. https://doi.org/10.1007/s00198-020-05602-x
doi: 10.1007/s00198-020-05602-x
pubmed: 33230576
pmcid: 7075819
Iversen MD, Vora RR, Servi A, Solomon DH (2011) Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. J Geriatr Phys Ther 34:72–81. https://doi.org/10.1097/JPT.0b013e3181ff03b4
doi: 10.1097/JPT.0b013e3181ff03b4
pubmed: 21937896
pmcid: 3181084
Forbes CA, Deshpande S, Sorio-Vilela F, Kutikova L, Duffy S, Gouni-Berthold I, Hagström E (2018) A systematic literature review comparing methods for the measurement of patient persistence and adherence. Curr Med Res Opin 34:1613–1625. https://doi.org/10.1080/03007995.2018.1477747
doi: 10.1080/03007995.2018.1477747
pubmed: 29770718
Cornelissen D, de Kunder S, Si L, Reginster JY, Evers S, Boonen A, Hiligsmann M, European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) (2020) Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int 31:1645–1669. https://doi.org/10.1007/s00198-020-05378-0
doi: 10.1007/s00198-020-05378-0
pubmed: 32358684
pmcid: 7423788